Results 261 to 270 of about 141,118 (333)

Intrapartum Antibiotic Prophylaxis and Child Health Outcomes: A Systematic Review and Meta‐Analysis of Observational Studies

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background With increasing use of intrapartum antibiotic prophylaxis (IAP) for the prevention of early‐onset Group B streptococcus (GBS) infections, there is concern about its long‐term consequences on child health. Objectives To synthesise the evidence of IAP exposure on autoimmune‐related diseases, obesity in childhood and microbial ...
Maedeh Moradi, Jessica A Grieger, Xiao Tong Teong, Leonie K Heilbronn   +3 more
wiley   +1 more source

Crowdsourcing is Acceptable to Develop Pre-Exposure Prophylaxis Promotions in Alabama: A Qualitative Study with Sexual Minority Men and Sexual Health Providers. [PDF]

J Int Assoc Provid AIDS Care
Joseph KM, Elopre L, Matthews LT, Van Der Pol B, Tucker JD, Gravett RM.   +5 more
europepmc   +1 more source

Timing of Intrapartum Antibiotics at Caesarean Section and Risk of Asthma, Eczema and Allergic Rhinitis: Results From a Natural Experiment

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To investigate whether the risk of asthma, eczema and allergic rhinitis at 5 years in children born by caesarean section (CS) differs by the timing of antibiotic administration to the mother (pre‐incision vs. post‐cord clamping). Design Natural experiment using birth cohort data. Setting UK single centre population‐based birth cohort.
Lucy Pembrey, Gillian Santorelli, Sergio Souza da Cunha, Sam Oddie, Emily S. Petherick, Neil Pearce, Amy Hough, John Wright   +7 more
wiley   +1 more source

Drug Use After Emergency Department‐Initiated Injectable Buprenorphine: A Secondary Analysis of the ED‐INNOVATION Ancillary Safety and Feasibility Trial

Academic Emergency Medicine, EarlyView.
ABSTRACT Study Objective To characterize opioid and nonopioid drug use in the week following emergency department (ED)‐initiated extended‐release buprenorphine (XR‐BUP) treatment using both self‐reported data and urine drug screens (UDS). Methods This study uses data collected during a nonrandomized clinical trial of patients with untreated opioid use ...
Ethan Cowan, Gail D'Onofrio, Jeanmarie Perrone, Erik Anderson, James Dziura, Kathryn Hawk, Andrew Herring, Ryan McCormack, Manali Phadke, Elizabeth A. Samuels, David A. Fiellin   +10 more
wiley   +1 more source

I Don't Really Know Much About PrEP: Examining Black HBCU Women's Pre-Exposure Prophylaxis Knowledge and Awareness. [PDF]

Int J Environ Res Public Health
Robinson MN, Williams BM, Aidoo-Frimpong G, Blockett RA, Lowery CR, Sandoval-Rosario M, Chandler R.   +6 more
europepmc   +1 more source

Substance Use and Sex Index version 2 (SUSI‐2): Validation of a brief questionnaire for the measurement of behaviours associated with transmission of blood borne viruses and sexually transmitted infections

Addiction, EarlyView.
Abstract Aims This study sought to validate a community‐acceptable Substance Use & Sex Index (SUSI) for use in substance use intervention research. SUSI aims to measure behaviours associated with the transmission of blood‐borne viruses (BBV) and sexually transmitted infections (STI) among people who use substances and incorporate contemporary sexual ...
Brendan Clifford, Raimondo Bruno, Liam Acheson, Michael E. Cecilio, Krista J. Siefried, Jack Freestone, Vincent J. Cornelisse, Brendan Crozier, Nicky Bath, Nadine Ezard   +9 more
wiley   +1 more source

Trastuzumab Deruxtecan for HER2‐Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern, Elgene Lim, Sunil Lakhani, Nirmala Pathmanathan, Sudarsha Selva‐Nayagam, Nicole McCarthy, Belinda Yeo, Benjamin Dessauvagie, Gelareh Farshid   +8 more
wiley   +1 more source

A cross-sectional survey to explore healthcare providers' experiences and attitudes toward HIV pre-exposure prophylaxis for women in family planning centers of Greater Paris. [PDF]

PLoS One
Liegeon G, Mason JA, Friedman EE, Toribio M, Florence S, Villalon E, Castaneda J, Ramírez Zamudio A, Devlin SA, Ridgway JP, Johnson AK, Manda V.   +11 more
europepmc   +1 more source

In-utero exposure to tenofovir disoproxil fumarate pre-exposure prophylaxis and growth metrics in HIV unexposed breastfed infants in South Africa: a post hoc analysis of the CAP 016 PrEP in pregnancy RCT

Megeshinee Naidoo, Kimesh Naidoo, Carl Lombard, Alicia C. Desmond, Richard Clark, James F. Rooney, Glenda Gray, Dhayendre Moodley   +7 more
openalex   +1 more source

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan, Jianguo Sun, Makoto Kawashima, You Chan Kim, Mison Chun, Chia‐Yu Chu, Yi‐Hsin Liang, Mee Chang, Delphine Kerob, Brigitte Dreno   +9 more
wiley   +1 more source